Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corporation (Nasdaq: ADPT) develops and commercializes products and services based on sequencing and interpreting the adaptive immune system. Its clonoSEQ test measures minimal residual disease in patients with lymphoid cancers, helping clinicians monitor disease and assess treatment response;… From the company’s description.
Over the twelve months to Sep 30, 2026, Adaptive Biotechnologies Corp reported revenue of $298.01M, up 17.9% from a year earlier, and a net loss of $70.73M. Its operating margin was −16.2%, and operations used $4.28M in cash. In fiscal 2025, it reported revenue of $276.98M, up 54.8% from fiscal 2024, and a net loss of $59.46M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Adaptive Biotechnologies Corp does
In the company’s own words
Adaptive Biotechnologies Corporation (Nasdaq: ADPT) develops and commercializes products and services based on sequencing and interpreting the adaptive immune system. Its clonoSEQ test measures minimal residual disease in patients with lymphoid cancers, helping clinicians monitor disease and assess treatment response; the company also provides the assay to biopharmaceutical partners for use in clinical trials. Its Immune Medicine business offers immune-receptor sequencing, data licensing, T-cell receptor–antigen prediction models and target discovery services to research and biopharmaceutical customers. The company is organized into two businesses: MRD, comprising clinical testing and MRD Pharma, and Immune Medicine, which applies its immune-receptor data and technologies to research and product development. In 2025, revenue was $277.0 million, including $212.3 million from MRD. During that year, clonoSEQ was used in more than 180 active trials conducted by over 40 biopharmaceutical partners. The company’s proprietary datasets include more than five million T-cell receptor–antigen matches.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- SEATTLE, WA
- Fiscal year end
- December
- CIK
- 1478320
- SIC
- 2836
Financial performance, year by year
Fiscal 2019–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Adaptive Biotechnologies Corp — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Adaptive Biotechnologies Corp · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Adaptive Biotechnologies Corp’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Adaptive Biotechnologies Corp’s bonds, as funds hold them
Funds report holding 1 issues of Adaptive Biotechnologies Corp’s debt, $1.98M at market value — what funds hold, not the company’s total debt.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Adaptive Biotechnologies Corp and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Adaptive Biotechnologies Corp's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Adaptive Biotechnologies Corp's last four quarterly filings that the numbers alone won't show?”